University of Colorado Cancer Center Study Hints at New Target to...

Eya3 inhibition could be an attractive strategy to increase effectiveness of anti-PD-L1 immunotherapies against triple-negative breast cancer.(PRWeb May 14, 2018)Read the full story at https://www.prweb.com/releases/2018/05/prweb15477653.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news